BioNTech’s Oncology Promise Meets the Market’s Demand for Proof
Published on 06/08/2026 at 10:00 | Redaktion boerse-global.de
The gap between where BioNTech trades and where analysts say it should be has become a chasm of credibility. At €75.85, the stock sits roughly 28% below its January high of €105.80, yet the consensus price target of €107.41 implies an upside of more than 40%. That disconnect is not a quirk of short-term volatility—it is the central tension of a company that no longer commands the pandemic premium but has yet to prove its post-COVID identity.
The market’s message is blunt: scientific optionality no longer earns an automatic valuation lift. BioNTech’s shares have shed 3.8% in the past week, 4.53% over the past month, and 8% since the start of the year. The 12-month decline exceeds 20%. This is not a weak biotech tape; it is a sector-wide demand for evidence over ambition. The stock now trades 6.4% below its 50-day moving average of €81.06 and nearly 12% below the 200-day average of €85.88. The relative strength index of 38.4 signals pressure, not panic, while annualized 30-day volatility of 27.5% keeps traders engaged without tipping into a rout.
The most telling operational signal came not from oncology but from the COVID franchise. Pfizer and BioNTech halted a US trial of their updated vaccine—not for safety reasons, but because recruitment was too slow. The product remains commercially and medically relevant, but the environment has shifted: lower demand, stricter evidence requirements, and a capital market with little patience for protracted transitions. The FDA has issued formulation recommendations for the next US vaccination season targeting a monovalent shot against the XFG variant of the JN.1 lineage, and BioNTech is adapting accordingly. But the era when vaccine sales drove structural growth is over.
That makes the oncology pipeline the only credible escape route. The most concrete milestone is BNT323 (trastuzumab pamirtecan), an antibody-drug conjugate developed with DualityBio that targets HER2-expressing endometrial cancer. BioNTech and DualityBio plan to file a US approval application in 2026, pending FDA feedback. Phase 2 data showed a confirmed overall response rate of 47.9% across all HER2 levels, rising to 49.3% in patients who had previously received an immune checkpoint inhibitor. Median progression-free survival reached 8.1 months. In the highest HER2 expression group (IHC 3+), response exceeded 70%. Crucially, the drug also showed activity at lower HER2 levels: 33.9% for IHC 1+ and 40.4% for IHC 2+. No approved HER2-directed therapy currently covers those patients, giving BioNTech a potential differentiation edge against AstraZeneca and Daiichi Sankyo’s Enhertu, which is only approved for IHC 3+.
Should investors sell immediately? Or is it worth buying BioNTech?
BNT323 is just one piece of a broader buildout. BioNTech now runs more than two dozen mid- and late-stage trials, including 13 registration-enabling programs. At ASCO in Chicago, the company presented data from the ROSETTA Lung-02 study, showing encouraging antitumor activity for pumitamig combined with chemotherapy in untreated non-small cell lung cancer. Gotistobart, a CTLA-4 candidate, showed durable activity in platinum-resistant ovarian cancer. The goal is ambitious: approval in ten cancer indications by 2030, a target set by the new management generation as founders Ugur Sahin and Ă–zlem TĂĽreci prepare to step back from operational roles by the end of 2026.
Financing that pipeline requires painful restructuring. BioNTech is vacating sites in Idar-Oberstein, Marburg, and Tübingen by the end of 2027, winding down operations in Singapore in the first quarter of 2027, and closing the CureVac facility. Up to 1,860 jobs are affected. The restructuring is expected to generate annual savings of €500 million from 2029 onward, with most freed-up cash redirected to the pipeline. CFO Ramón Zapata has confirmed that Pfizer will handle all COVID vaccine supply from its existing capacity from the end of 2026. First-quarter revenue fell to €118.1 million from €182.8 million a year earlier, though the company maintains its full-year guidance of €2.0 billion to €2.3 billion. A $1.0 billion share buyback program is underway, and BioNTech ended March with roughly €16.8 billion in liquidity.
Analysts remain split on timing. UBS upgraded BioNTech to Buy ahead of ASCO, raising its price target to $135 from $117, betting on the late-stage oncology pipeline. Bernstein’s Jeffrey Walch initiated at Market Perform with a $96 target, arguing that upside is limited until key clinical milestones are reached. The stock’s 12-month decline of 19.53% and a 10.82% discount to the 200-day average reflect that uncertainty.
BioNTech at a turning point? This analysis reveals what investors need to know now.
BioNTech is not being written off as a failure; it is being revalued as a transition story. At €76.65, the market is saying clearly: conviction requires evidence, not potential. The FDA filing for BNT323 in 2026 will be the first hard test of whether that evidence arrives in time to close the gap.
Ad
BioNTech Stock: New Analysis - 8 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
